In April, we covered the Section 232 pharmaceutical tariff proclamation as a developing situation, legally grounded, but still taking shape through manufacturer negotiations. Today, July 31st, is the first effective date. For health plans, TPAs, and self-funded employers managing specialty drug costs, the picture is now clearer than it was four months ago, and one piece of it changed significantly last week.
What Took Effect Today
The April 2nd proclamation imposed 100% tariffs on patented pharmaceuticals and their active pharmaceutical ingredients under Section 232. Today’s effective date applies to 17 large pharmaceutical companies listed in Annex III of the proclamation. All other covered importers face a September 29th effective date.
The tariff structure is tiered, not flat. The 100% rate is the default, but it isn’t what every company faces. Thirteen companies signed company-specific agreements with the administration before April 2nd and are operating under their own terms under Annex II. Companies that commit to domestic manufacturing and MFN pricing agreements with HHS can access a reduced rate of 20% rather than the 100% default. Companies can pursue preferential tariff treatment through 2029 by striking those deals with the administration.
The Supreme Court’s February 2026 ruling striking down IEEPA-based tariffs did not affect these. Section 232 operates under separate statutory authority, and these tariffs are permanent until affirmatively removed by the President.
Generics, biosimilars, and orphan drugs remain expressly excluded from the Section 232 tariffs, for now. That “for now” carries more weight than it did in April.
What Changed Last Week
On July 21st, ten days before today’s effective date, the administration announced a phased tariff plan for generic pharmaceuticals. The timeline: zero tariffs through August 2028, 100% for one year from August 2028 to August 2029, then 200% thereafter, for companies that have not committed to domestic US manufacturing.
This is a material development. When we covered the April proclamation, the patented/generic split was the structural feature that defined the tariff’s scope for specialty drug cost planning. Patented biologics and specialty drugs: subject to tariff. Generics and biosimilars: exempt. That split was the basis for the financial planning question we raised.
The July 21st announcement puts a timeline on the generic exemption. It doesn’t take effect for two years, and it’s framed as leverage for domestic manufacturing commitments rather than a settled policy outcome. But for organizations doing any planning that extends into 2028 and beyond formulary strategy, biosimilar transition timelines, long-term cost modeling the assumption that generics and biosimilars are permanently outside this framework is now less certain than it was.
What This Means for Specialty Drug Cost Planning
The near-term picture for patented specialty drugs under the medical benefit is that cost uncertainty has increased. How much depends on which specific drugs are in the book, which manufacturers supply them, and whether those manufacturers have signed onshoring agreements that bring their rate below 100%.
That last variable matters more than the headline rate. According to PharmExec, companies that negotiated onshoring agreements before the July 31st deadline can reduce their effective tariff rate to 20%, a significant difference from the default. The practical impact on any given drug depends on whether its manufacturer is operating under an agreement, what country the API originates from, and how the manufacturer has structured its supply chain in response to the proclamation.
For the September 29th cohort, the broader universe of pharmaceutical importers who aren’t among the 17 Annex III companies, there are still 60 days before tariffs take effect. That window will continue producing negotiated agreements, announced onshoring commitments, and company-specific rate structures that further vary the real-world impact.
The honest summary for health plans, TPAs, and self-funded employers: the 100% tariff rate is the legal structure, but what any specific organization actually experiences in drug costs will depend on drug-by-drug, manufacturer-by-manufacturer outcomes that are still being negotiated. Organizations that know which patented specialty drugs are running through their medical benefit, and which manufacturers supply them, are in a better position to assess exposure than those managing from summary-level reporting.
The biosimilar and generic picture warrants a separate note. Nothing in the July 21st generic tariff announcement changes near-term cost assumptions. The two-year window is real. But formulary and benefit design decisions being made now that extend into 2028 are being made under different assumptions than existed in April.
We said in April we’d return to this as the policy became clearer. If you’re tracking manufacturer-level developments that are affecting your specialty drug cost planning, we’d like to hear what you’re seeing. Comment below.
Disclaimer: This newsletter is provided by VativoRx for informational and educational purposes only and does not constitute legal, regulatory, clinical, or financial advice. VativoRx is not affiliated with any government agency or program referenced. Tariff policy details are evolving; the information above reflects publicly available sources as of July 31, 2026. Readers should consult their legal, trade, and financial advisors regarding specific circumstances.